Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plinabulin (Primary) ; Docetaxel; Pegfilgrastim
  • Indications Neutropenia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms Protective-1
  • Sponsors BeyondSpring Pharmaceuticals

Most Recent Events

  • 06 Jun 2023 Pooled analysis of NCT02504489; NCT03102606; NCT00630110 trials presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 13 Dec 2022 According to BeyondSpring Pharmaceuticals media release, data of this study was presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) and at ESMO Asia Congress 2022.
  • 13 Sep 2022 Results by obtaining data from PROTECTIVE-1 and PROTECTIVE-2, evaluating plins protective effects on granulocyte-monocyte progenitor , presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top